Amicus Therapeutics (FOLD) Competitors $8.33 -0.15 (-1.77%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$8.28 -0.05 (-0.60%) As of 09/19/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD vs. MDGL, HALO, RGEN, ALKS, LGND, MNKD, BCRX, CLDX, NVAX, and INVAShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Alkermes Ligand Pharmaceuticals MannKind BioCryst Pharmaceuticals Celldex Therapeutics Novavax Innoviva Amicus Therapeutics (NASDAQ:FOLD) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Which has better earnings and valuation, FOLD or MDGL? Amicus Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.29M4.86-$56.11M-$0.12-69.42Madrigal Pharmaceuticals$515.55M18.95-$465.89M-$12.85-34.24 Does the media favor FOLD or MDGL? In the previous week, Amicus Therapeutics had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Amicus Therapeutics and 6 mentions for Madrigal Pharmaceuticals. Amicus Therapeutics' average media sentiment score of 0.77 beat Madrigal Pharmaceuticals' score of 0.71 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, FOLD or MDGL? Amicus Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, meaning that its share price is 202% less volatile than the S&P 500. Do analysts prefer FOLD or MDGL? Amicus Therapeutics presently has a consensus price target of $15.78, suggesting a potential upside of 89.41%. Madrigal Pharmaceuticals has a consensus price target of $483.38, suggesting a potential upside of 9.88%. Given Amicus Therapeutics' higher probable upside, research analysts plainly believe Amicus Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Do institutionals & insiders have more ownership in FOLD or MDGL? 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is FOLD or MDGL more profitable? Amicus Therapeutics has a net margin of -6.67% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Amicus Therapeutics' return on equity of -5.07% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-6.67% -5.07% -1.23% Madrigal Pharmaceuticals -54.68%-38.38%-27.32% SummaryAmicus Therapeutics beats Madrigal Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.57B$3.16B$5.80B$10.47BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-69.417.5160.1622.83Price / Sales4.86430.77530.27121.65Price / CashN/A44.8326.0131.15Price / Book12.829.6215.776.42Net Income-$56.11M-$53.02M$3.30B$271.73M7 Day Performance4.26%3.12%5.35%3.51%1 Month Performance9.61%6.25%7.28%9.59%1 Year Performance-26.22%11.20%80.88%28.60% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics3.9477 of 5 stars$8.33-1.8%$15.78+89.4%-26.2%$2.57B$528.29M-69.41480News CoverageAnalyst UpgradeHigh Trading VolumeMDGLMadrigal Pharmaceuticals3.9463 of 5 stars$425.60-1.5%$483.38+13.6%+88.4%$9.60B$180.13M-33.1290HALOHalozyme Therapeutics4.5613 of 5 stars$76.33-0.7%$67.11-12.1%+31.3%$8.99B$1.02B17.47390News CoveragePositive NewsRGENRepligen4.8384 of 5 stars$113.74+0.2%$166.67+46.5%-14.5%$6.39B$634.44M-454.941,778Positive NewsALKSAlkermes4.5899 of 5 stars$26.52-1.7%$41.85+57.8%-2.7%$4.45B$1.56B12.751,800Positive NewsLGNDLigand Pharmaceuticals4.2143 of 5 stars$165.51-0.1%$176.50+6.6%+62.0%$3.25B$167.13M-41.3880News CoveragePositive NewsHigh Trading VolumeMNKDMannKind4.2682 of 5 stars$5.38-3.4%$11.17+107.6%-17.7%$1.71B$285.50M48.91400Positive NewsAnalyst ForecastInsider TradeShort Interest ↓BCRXBioCryst Pharmaceuticals4.265 of 5 stars$7.70-2.7%$16.70+116.9%-5.1%$1.66B$450.71M-42.78530Positive NewsCLDXCelldex Therapeutics2.105 of 5 stars$24.50+0.2%$46.67+90.5%-40.3%$1.62B$7.02M-8.14150Positive NewsAnalyst ForecastNVAXNovavax4.1922 of 5 stars$8.08+1.3%$14.29+76.8%-32.5%$1.30B$682.16M3.541,990INVAInnoviva4.7715 of 5 stars$19.55+0.9%$42.75+118.7%-0.9%$1.22B$358.71M63.07100Positive NewsAnalyst UpgradeShort Interest ↓ Related Companies and Tools Related Companies MDGL Alternatives HALO Alternatives RGEN Alternatives ALKS Alternatives LGND Alternatives MNKD Alternatives BCRX Alternatives CLDX Alternatives NVAX Alternatives INVA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FOLD) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FOLD Stock Alerts